• Je něco špatně v tomto záznamu ?

The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024

M. Miszczyk, P. Rajwa, T. Fazekas, A. Briganti, PI. Karakiewicz, M. Rouprêt, SF. Shariat

. 2024 ; 7 (6) : 1195-1198. [pub] 20240424

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003340

In the past, selection of intermediate clinical endpoints (ICEs) in prostate cancer (PCa) trials largely depended on qualitative assessments; however, the advancing quality of research necessitates a robust correlation with overall survival (OS). This review summarises the results from several high-quality meta-analyses that explored the validity of ICEs as surrogates for OS. We found strong evidence that metastasis-free survival can serve as an ICE in localized PCa. In advanced disease, valid ICEs were identified only within the context of metastatic hormone-sensitive PCa, including radiological and clinical progression-free survival; however, concerns remain regarding their use owing to the limited generalisability of the data used to validate their surrogacy. PATIENT SUMMARY: Intermediate clinical endpoints can reduce the costs of trials and allow earlier introduction of new treatment methods. This article summarises results from studies verifying the validity of these endpoints as surrogates for overall survival.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003340
003      
CZ-PrNML
005      
20250206104256.0
007      
ta
008      
250121s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euo.2024.04.004 $2 doi
035    __
$a (PubMed)38664138
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Miszczyk, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland
245    14
$a The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024 / $c M. Miszczyk, P. Rajwa, T. Fazekas, A. Briganti, PI. Karakiewicz, M. Rouprêt, SF. Shariat
520    9_
$a In the past, selection of intermediate clinical endpoints (ICEs) in prostate cancer (PCa) trials largely depended on qualitative assessments; however, the advancing quality of research necessitates a robust correlation with overall survival (OS). This review summarises the results from several high-quality meta-analyses that explored the validity of ICEs as surrogates for OS. We found strong evidence that metastasis-free survival can serve as an ICE in localized PCa. In advanced disease, valid ICEs were identified only within the context of metastatic hormone-sensitive PCa, including radiological and clinical progression-free survival; however, concerns remain regarding their use owing to the limited generalisability of the data used to validate their surrogacy. PATIENT SUMMARY: Intermediate clinical endpoints can reduce the costs of trials and allow earlier introduction of new treatment methods. This article summarises results from studies verifying the validity of these endpoints as surrogates for overall survival.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty $x mortalita $x terapie $x patologie $7 D011471
650    _2
$a stanovení cílového parametru $7 D023381
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Rajwa, Paweł $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
700    1_
$a Fazekas, Tamás $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Canada
700    1_
$a Rouprêt, Morgan $u GRC 5 Predictive Onco-Uro, Sorbonne University, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Research Centre for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: shahrokh.shariat@meduniwien.ac.at
773    0_
$w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 7, č. 6 (2024), s. 1195-1198
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38664138 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104251 $b ABA008
999    __
$a ok $b bmc $g 2263233 $s 1239347
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 7 $c 6 $d 1195-1198 $e 20240424 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace